Cortexyme Selects 3CLpro Inhibitor COR803 For Treatment Of Coronavirus Infection

Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative

byBill Haddad

July 23, 2021

1 minute read

Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

By Vandana Singh

December 13, 1:11 PM

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with

HARP

Singular Genomics G4 Launch Impresses BofA Analyst: What’s Next?

By Priya Nigam

January 7, 5:18 PM

Singular Genomics Systems Inc (NASDAQ: OMIC) launched the G4 system in late December and has begun taking orders, with shipments expected to commence in the second quarter of 2022, according to BofA Securities.

OMIC

NASA Administrator Praises Elon Musk’s SpaceX For Proving Critics Wrong: ‘Everybody Poo-Pooed’ The Private Space Company

By Adam Eckert

September 12, 5:33 PM

NASA Administrator Bill Nelson has praised Tesla Inc (NASDAQ: TSLA) CEO Elon Musk for the incredible rise of SpaceX in the private space industry, despite being written off by critics.

AMZN